Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase II/III trial of a house dust mite allergy immunotherapy tablet in patients with house dust mite-induced allergic rhinitis

Trial Profile

Pivotal phase II/III trial of a house dust mite allergy immunotherapy tablet in patients with house dust mite-induced allergic rhinitis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 08 Nov 2021 Results of pooled post hoc analysis comparing efficacy and safety of the HDM SLIT-tablet between adults and adolescents by using data from two studies (NCT01700192 an JapicCTI21848) presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
    • 01 Mar 2021 Results assessing efficacy and safety data from 2 clinical trials (NCT01700192 and JapicCTI121848), presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 06 Mar 2017 A Subgroup Analysis of Results from a DBPC Phase III Trial presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top